Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Characteristics and clinical outcomes of patients (pts) with Acute Myeloid Leukemia (AML) with Mecom rearrangements: An analysis from the MARROW consortium

View Full Paper
Ask AI
Bookmark
Share

Authors

JGJesus D. Gonzalez‐LugoAAAlexander J. AmbinderKMKrzysztof Mrózek

Discussion

Loading...

Member takes

Overview

Analysis reveals poor clinical outcomes in acute myeloid leukemia with MECOM rearrangements treated with hypomethylating agents and venetoclax, suggesting a need for new treatment strategies.

Key Points

  • Overall survival among patients treated with intensive chemotherapy was better than those given venetoclax or hypomethylating agent monotherapy, pointing to a treatment gap.
  • Among 224 patients, the highest composite complete remission was 54% in patients receiving intensive chemotherapy, revealing treatment effectiveness nuances.
  • The analysis involved molecular characteristics from real-world data across major US Cancer Centers, supporting external validation.
  • Results underscore the urgent need for alternative therapies in acute myeloid leukemia with MECOM rearrangements due to poor outcomes across regimens.

Cite This Study

Gonzalez‐Lugo et al. (2025) studied this question.

synapsesocial.com/papers/69362f484fa91c937236d6fehttps://doi.org/10.1182/blood-2025-294
View Full Paper
Ask AI
Bookmark
Share